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INTRODUCTION Nanoparticles may serve as a promising means to deliver novel
therapeutics to the myocardium following myocardial infarction. We assessed
whether lipid-based liposomal nanoparticles speciﬁcally target injured myocardium
following intravenous injection.
METHODS CD1 male mice that underwent LAD ligation surgery with 45 minutes of
ischemia followed by reperfusion (I/R) and then received tail-vein injection 24 hours
following surgery with either Gd-DTPA labeled, ﬂuorescent NBD-labeled liposomes
(n¼7) or a saline vehicle control (n¼7). The hearts were harvested 24 hours later and
underwent T1 and T2-weighted ex vivo MR imaging using a 7 Tesla Bruker magnet.
The hearts were the sectioned for immunohistochemistry and also optical ﬂuorescent
imaging using an IVIS imaging system.
RESULTS The mean size of the liposomes was 100 nm by dynamic light scattering.
T1-weighted imaging demonstrated a signiﬁcant increase in signal intensity in the
LAD territory vs the posterior wall with liposomes compared with control (41 10%
vs 9 2%, p¼0.009). Optical imaging demonstrated signiﬁcant increase in the LAD
territory vs the posterior wall for animals that received liposomes compared with
those that received control (16331% vs 1314%, p¼0.001). The Figure shows T1-
weighted MR images and optical images below. Fluorescent microscopy demon-
strated the presence of green ﬂuorescence consistent with NBD-labeled liposomes
within the infarct area of hearts from mice that received liposomes while there
was no green ﬂuorescence in the hearts of mice that received injection of saline
control.
CONCLUSIONS Following a murine model of MI, liposomes trafﬁc to the heart and
preferentially home to regions of myocardial injury. These liposomes can be loaded
with therapeutic agents to deliver novel agents directly to regions of myocardial
injury.TECHNOLOGYBIODEGRADABLE POLYMERS
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BACKGROUND A conﬂuent endothelium is needed to reduce thrombosis in vascular
grafts, including EVAR stent-grafts. A pilot study was designed to assess the tissue
formation and cellular response to an endovascular stent-graft containing a bio-
absorbable graft material designed to treat aneurysms through endovascular tissue
regeneration. The objective of the study was to determine the in vivo response of the
graft material in an AAA model.
METHODS A peritoneal patch was used to form an AAA in swine for 2 weeks then
treated with the bioabsorbable stent-graft (n¼7). The stent-graft consisted of a syn-
thetic polymer graft material sutured to a stent (Megalink, Guidant, USA). The stent-
graft was delivered endovascularly using an 11F sheath with a dilation catheter
(Powerﬂex P3, Cordis, USA). After treatment for 28 days, the animals were sacriﬁced
and the tissue was examined through both gross and microscopic histology to
determine the presence of endothelial cells (CD-31 antibody), smooth muscle cells
(SM a-actin antibody), collagen (Masson’s Trichrome) and any adverse tissue re-
sponses (H&E). Physical attachment of the graft to the vessel and gross appearance of
the lumen surface were also noted.
RESULTS The stent-grafts placed endovascularly demonstrated no evidence of blood
ﬂow into the aneurysmal sac upon deployment, based on angiography and ultrasound
imaging. During the course of the study, no endoleaks were observed in the treated
animals. Upon gross examination after sacriﬁce at 28 days, the graft material
appeared well adhered to the aorta with a shiny, white appearance on the lumen
surface. No evidence of thrombi was noted. The graft demonstrated a conﬂuent
endothelial lining as evidenced by histologic staining for CD-31 antibody which
positively stained a single layer of cells on the lumen surface. The new endothelium
was supported by a thin neointima consisting of collagen. In addition, the SM a-actin
antibody stain indicated the presence of smooth muscle cells on the abluminal
portion of the graft with cells penetrating the porous graft material. No signiﬁcant
adverse tissue response was noted. The graft material was integrated with the vessel
wall and grossly intact without any defects or degradation.
CONCLUSIONS A stent-graft containing a bioabsorbable graft material was success-
fully deployed endovascularly in a surgical swine model. The results of our pilot
study suggest that aneurysms may be treated using an appropriate bioabsorbable
material for endovascular tissue regeneration.BIODEGRADABLE SCAFFOLDS
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AIMS BMS and DES overlap is associated with impaired clinical outcomes at long-
term follow-up, whereas data on the impact of overlap with overlapping everolimus-
eluting bioresorbable vascular scaffold (Absorb BVS) are scant. We report the
procedural and mid-term clinical outcomes in a cohort of patients having at least one
vessel treated with 2 overlapped Absorb BVS.
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Italy were systematically followed for major adverse cardiac events (MACE). Clinical
data were obtained for 92 patients (mean age 57.1 years, 74.0% males) with a total of
95 lesions treated with overlapping Absorb BVS. Fifty-seven (61.9%) patients under-
went scaffold implantation due to acute coronary syndrome. Diabetic patients were
17.3%. Multivessel disease was present in 63.0% of patients. Treated lesions were
type B1 (21.3%), type B2 (23.0%), and type C (55.7%). Mean length covered by over-
lapping BVS was 48.0 16 mm. The mean number of implanted Absorb BVS was 2.25
scaffolds per lesion and 2.63 scaffolds per patient. Angiographic and procedural
success occurred in all patients. At a median follow up of 10 months (interquartile
range, 5-14.75 months), cumulative occurrence of MACE was 4.34%. Adverse events
were: 1 possible late scaffold thrombosis (unexplained cardiac death occurring two
months after elective revascularization), 2 TLR due to BVS restenosis (documented
BVS recoil in 1 case), 1 TVR due to restenosis of drug eluting stent proximal to two
overlapped scaffolds.
CONCLUSIONS Our ﬁndings suggest that treatment of long lesions by means of
overlapped Absorb BVS appears to be safe at mid-term follow up.DRUG ELUTING STENTS
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BACKGROUND Percutaneous coronary intervention (PCI) of small vessels is associ-
ated with a high restenosis rate. Drug-eluting stents (DES) reduce restenosis in
coronary arteries, but the role of DES in small coronary vessels has not been well
deﬁned. In our systematic review, we aim to summarize all known angiographic and
clinical outcome of 2.25-mm DES, to highlight the need for speciﬁc outcome data in
this cohort.
METHODS A systematic literature search of 394 relevant citations from PubMed,
EMBASE, Web of Science and the Cochrane Central Register of Controlled
Trials yielded 8 eligible studies studying FDA approved 2.25-mm DES. Angiographic
and clinical outcome data were extracted and compared between each type
of DES. Subgroup analysis comparing clinical outcome between sirolimus-eluting
stents (SES) and paclitaxel-eluting stents (PES) was done using a random effects
model.
RESULTS Of the 8 studies included in the analysis, 6 were non-randomized and 2
were randomized against bare-metal stents (BMS). A total of 1,037 patients were
studied, with follow-up ranging from 1 month to 5 years. PES, SES and everolimus-
eluting stents (EES) were studied. Myocardial infarction at one year was highest in
PES vs. SES and EES: 4.2% vs. 3.4% and 1.5%. Target vessel revascularization at one
year was highest in PES vs. SES and EES: 13.8% vs. 5.7% and 8.8%. Death rate was
highest in PES at 4.2% vs. SES and EES (3.4% and 1.5%). Mean late lumen loss for PES,
SES, and EES was 0.280.11 mm, 0.150.11 mm, and 0.160.41 mm at 9 months to 1
year. Mean diameter stenosis for PES, SES and EES was 34.74.2%, 29.56.2%, and
20.922.5%. Mean binary stenosis for PES, SES and EES was 26.97.8%, 10.46.7%,
and 9.6% respectively. No 2.25 mm speciﬁc data was available for zotarolimus eluting
stents, which was reported in combination with larger stent sizes.
CONCLUSION Our composite data suggest that 2.25-mm SES and EES have superior
clinical and angiographic outcomes compared with 2.25-mm PES, which has been
shown to be superior to BMS in a randomized controlled study. Given the unique
theoretical challenges posed by small vessel PCI, the overall lack of randomized data
in this cohort needs to be addressed with future studies evaluating 2.25 mm stents in
next-generation DES.
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Republic ofBACKGROUND There have been limited data comparing efﬁcacy and safety of Bio-
limus-eluting Stents (BES, BiomatrixTM, Biosensors and NoboriTM, Terumo) with
Platinum Chromium Everolimus-eluting Stent (PtCr-EES, Promus ElementTM, Boston
Scientiﬁc) in a series of Asian population in real world clinical practice.
METHODS A total of 626 patients (pts) receiving BES or PtCr-EES were pooled from
our prospective percutaneous coronary intervention (PCI) registry from March 2008
to May 2013. To adjust potential confounders, a propensity score matched (PSM)
analysis was performed using the logistic regression model, and clinical outcomes
were compared between the two groups up to 12 months.
RESULTS After PSM analysis, 2 propensity-matched groups (149 pairs, n ¼ 298 pts, C-
statistic¼0.793) were generated and the baseline characteristics of the two groups
were balanced. Six to 9-month angiographic outcomes showed that the incidence of
binary in-stent restenosis was higher in the BES group than PtCr-EES (18.9% vs. 7.0%,
p¼0.034). This adverse angiographic outcomes were translated into worse 12-month
clinical outcomes; the incidence of target lesion revascularizations (TLR: HR; 3.879,
C.I; 1.06-14.2, p¼0.041) and TLR-MACE (HR; 3.465, C.I; 1.103-10.88, p¼0.033) BA9
were signiﬁcantly higher than PtCr-EES despite of similar incidence of mortality and
myocardial infarction.
CONCLUSIONS As compared with PtCr-EES, BES seem to be associated with higher
rate of TLR and TLR MACE up to 12-month in a series of Asian population in real world
clinical practice.
Table. Mid-term angiographic and 12-month Clinical Outcomes after propensity score matched analysisCRT-704
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BACKGROUND Clinical trials and meta-analyses demonstrate the low restenosis and
stent thrombosis risks of next generation drug eluting stents (DES). Co-evolution of
device, delivery technique, and drug-related factors all contribute, yet relative ad-
vantages are difﬁcult to surmise. On a background of optimized contemporary bare
metal stents (BMS), we asked if locally eluted drugs are still as useful or if simple
design changes might obviate need for drug, further enhancing performance, man-
ufacturability, and cost.
METHODS We hypothesized that thin, bare metal cobalt chromium or platinum
chromium stents modiﬁed with an ultra-hydrophilic surface (UHS) treatment could
reduce late intimal hyperplasia (IH) as with second-generation DES, yet maintain fast
healing akin to bare metal stents (BMS). To test this, commercially available, FDA-
approved DES and BMS were compared with UHS in A) porcine coronary models to
assess IH and late thrombosis; and B) a rabbit iliac model to assess early healing and
subacute thrombosis.
RESULTS In vitro tests demonstrated similar to faster endothelialization with
reduced platelet adhesion (97% reduction, p<0.001) compared with untreated BMS.
Hydrophilic treatment reduced IH in porcine coronary arteries relative to 3 corre-
sponding BMS and DES platforms (2-3-fold reduction in 30-day angiographic reste-
nosis; p<0.03). In contrast to early healing of UHS and BMS (porcine 30-day
endothelialization score uniformly 4.0 of 4.0; conﬁrmed in rabbit), DES trended to
delayed healing at one month (range 2.67 to 4.0 out of 4.0) that resolved by 3 months,
correlating with computed drug-receptor saturation. Elevation in thrombotic indices
correlated with reduced endothelialization (p<0.0002) and occurred most often with
DES, never with UHS (Poisson probability¼0.135).
CONCLUSION Ultra-hydrophilic surface treatment of contemporary stents conferred
excellent healing while moderating neointimal and thrombotic responses. With
